Contribute Try STAT+ Today

Google on Tuesday debuted an artificial intelligence-powered dermatology tool that analyzes a user’s photos, asks a series of questions, and produces a list of possible causes. Although the tool, an app called “dermatology assist,” remains in the pilot stages in the U.S., Google has received approval from European regulators to market it as a low-risk medical device, enabling the tech giant to release it to some consumers as part of Google search later this year.

While Google executives and researchers expressed high hopes for the web-based tool at Google I/O, the company’s annual developer conference, several external researchers and clinicians shared a mix of cautious optimism and concern, including about how users will interpret the results and whether it will work equally well on a range of patients, given that the vast majority of dermatology training is performed using images and data from people with white skin. To date, U.S. regulators have yet to approve a single AI-powered dermatology device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.